Dr. Noveck is the Medical Director of the Duke Clinical Research Unit, Associate Professor of Medicine and the Co-Director of the Division of Clinical Pharmacology at Duke University Medical Center. He is a graduate of Louisiana State University School of Medicine in New Orleans where he received his medical degree and a graduate from Tulane University School of Medicine where he received his doctoral degree from the Department of Pharmacology and also completed a fellowship in Clinical Pharmacology. He was also an Assistant Medical Director at Bristol Laboratories in Syracuse, New York, where he was intimately involved in the preparation and NDA submission of butorphanol tartrate (Stadol%u2122). Additionally, Dr. Noveck is board certified in emergency medicine, clinical pharmacology and is a Certified Principal Investigator.
Previously, Dr. Noveck was the Medical Director of the Clinical Research Center in New Orleans, Louisiana before becoming a Senior Medical Director at MDS …Pharma Services. For the past 4 years he has served as the Principal Investigator and senior medical advisor for Daiichi Sankyo%u2019s Phase I clinical trials at their MDS affiliated site in Neptune, New Jersey. Dr. Noveck is also currently a Clinical Associate Professor of Medicine and Adjunct Associate Professor of Pharmacology at Tulane where he had been involved in teaching medical students. In addition, he was a member of the School of Medicine Admissions Committee for over 10 years.
Currently, Dr. Noveck is the Medical Director of the new Duke Clinical Research Unit, which is an academic early phase clinical pharmacology unit designed to explore new therapies for diseases in adult patients through adaptive clinical design and proof-of-concept clinical trials for both Duke Clinical Faculty and the pharmaceutical/biotech industries.
Dr. Noveck%u2019s experience in conducting first-in-man (healthy volunteer) and special (patient) population clinical trials brings a unique opportunity to the new Duke Clinical Research Unit to afford both the academic faculty members and the pharmaceutical/biotech industry opportunities not only to utilize a state-of-art clinical research unit, but also engage the expertise of the Duke medical faculty in order to facilitate clinical programs and generate quality data within scheduled timelines.
In addition, he has conducted over 30 clinical trials utilizing the Human Endotoxin Challenge Model in healthy subjects in order to better understand the clinical effects of new therapeutic drugs as well as to evaluate biomarkers of inflammation and sepsis.
Dr. Noveck is well published with over 40 peer-reviewed publications in the top pharmacology journals. He continues to be active in his field of clinical pharmacology and is an active member of the Society for Clinical Pharmacology and Therapeutics.